Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
pharmaphorum
APRIL 23, 2021
Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase.
52 
Let's personalize your content